Live Analyst Rating Changes 33655 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stan Berenshteyn
WF

Stan Berenshteyn

Wells Fargo
Wall Street Analyst
★★★★☆
#379
on 13Foresight · ranked by our own returns
56%
Success Rate
+8.3%
Average Return
27 of 48 calls profitable · +6.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 56% of Stan Berenshteyn's ratings turned a profit when each position was held for 1 year — averaging +8.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

64 Buy 25 Hold 1 Sell
Stan's Stock Coverage 15 ratings · 2026-09-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
OMDA
Omada Health, Inc.
 Sep 14, 2026 HOLD Strong Buy
+35.0% avg upside
13 analysts
$22.00
8.82% Upside
 -0.3% ·
VEEV
Veeva Systems
 Sep 09, 2026 BUY Buy
+4.9% avg upside
38 analysts
$330.00
27.61% Upside
 -0.2% ·
PHR
Phreesia
 Sep 03, 2026 HOLD Strong Buy
+70.8% avg upside
21 analysts
$10.00
0.67% Upside
 -7.4% ·
HQY
Healthequity
 Sep 03, 2026 BUY Strong Buy
+21.3% avg upside
20 analysts
$125.00
31.69% Upside
 -3.7% ·
PGNY
Progyny
 Aug 20, 2026 BUY Strong Buy
+23.4% avg upside
15 analysts
$37.00
38.27% Upside
 +4.5% ·
WAY
Waystar Holding Corp.
 Aug 19, 2026 BUY Strong Buy
+46.1% avg upside
30 analysts
$33.00
29.00% Upside
 +3.3% ·
HCAT
Health Catalyst
 Aug 13, 2026 HOLD Buy
+202.2% avg upside
15 analysts
$1.50
15.97% Downside
 +3.4% ·
CTEV
Claritev
 Aug 12, 2026 HOLD Strong Buy
+14.9% avg upside
8 analysts
$30.00
1.32% Downside
 -12.8% ·
DOCS
Doximity
 Aug 10, 2026 SELL Buy
+35.3% avg upside
28 analysts
$18.00
32.05% Downside
 -1.9% ·
AMWL
American Well
 Aug 05, 2026 BUY Hold
+19.6% avg upside
15 analysts
$16.00
18.38% Upside
 +4.7% ·
OMCL
Omnicell
 Jul 30, 2026 BUY Strong Buy
+52.3% avg upside
12 analysts
$50.00
55.90% Upside
 -13.2% ·
TDOC
Teladoc
 Jul 30, 2026 HOLD Buy
+361.7% avg upside
38 analysts
$6.00
4.23% Downside
 -4.3% ·
HNGE
Hinge Health, Inc. Class A
 Jun 24, 2026 BUY Strong Buy
+2.3% avg upside
17 analysts
$90.00
3.72% Downside
 +33.3% ·
GDRX
GoodRx Holdings
 Jun 02, 2026 BUY Buy
+281.4% avg upside
28 analysts
$3.50
3.42% Upside
 +14.9% ·
OSPN
OneSpan
 Oct 06, 2015 BUY Strong Buy
+41.6% avg upside
10 analysts
$34.00
93.88% Upside
 -4.5% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stan Berenshteyn — Frequently Asked Questions
How accurate are Stan Berenshteyn's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Stan's ratings were profitable over a one-year hold, with an average return of +8.3% per rating, or +6.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Stan ranked on 13Foresight?
Stan Berenshteyn is currently ranked #379 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stan cover?
Stan most recently has ratings on OMDA, VEEV, PHR, HQY, PGNY, WAY, HCAT, CTEV, DOCS, AMWL, OMCL, TDOC and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.